Volume 5.47 | Nov 28

Mammary Cell News 5.47 November 28, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
 
TOP STORY
MD Anderson Researchers Identify a Rescuer for Vital Tumor-Suppressor
A protector for PTEN, a tumor-thwarting protein often missing in cancer cells, has emerged from research. After establishing the relationship in cell lines and mouse model experiments, scientists found low levels of USP13 in human breast tumors correlate with lower levels of PTEN. [Press release from The University of Texas MD Anderson Cancer Center discussing online prepublication in Nature Cell Biology]
Press Release | Abstract
Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Phosphatidylethanolamine-Binding Protein 4 Is Associated with Breast Cancer Metastasis through Src-Mediated Akt Tyrosine Phosphorylation
Scientists found that metastatic MDA-MB-231 breast cancer cells expressed much higher levels of human phosphatidylethanolamine-binding protein 4 (hPEBP4) than nonmetastatic MCF-7 breast cancer cells and that expression levels of hPEBP4 were positively correlated with the metastasis of clinical breast cancer. [Oncogene] Abstract

Intracellular Patterns of Sialophorin Expression Define a New Molecular Classification of Breast Cancer and Represent New Targets for Therapy
Targeting sialophorin with small interfering RNA resulted in a MCF7 breast cancer cell line exhibiting increased homotypic adhesion, decreased transendothelial migration, increased susceptibility to apoptosis, increased vulnerability to lysis by natural killer cells and decreased ability to produce tumors in mice. [Brit J Cancer] Abstract

Vitamin C Suppresses Cell Death in MCF-7 Human Breast Cancer Cells Induced by Tamoxifen
Researchers investigated the role of vitamin C in tamoxifen (TAM)-mediated apoptosis. Pre-treatment with vitamin C caused a dose-dependent attenuation of cytotoxicity, as measured by acridine-orange/propidium iodide and Annexin V assay after treatment with TAM. [J Cell Mol Med] Abstract

The Adherens Junction Protein Afadin Is an Akt Substrate that Regulates Breast Cancer Cell Migration
Scientists showed that under conditions of physiological IGF-1 signaling and oncogenic PI 3-K and Akt, Afadin is phosphorylated by all Akt isoforms, and that this phosphorylation elicits a relocalization of Afadin from adherens junctions to the nucleus. Phosphorylation of Afadin also results in a marked increase in breast cancer cell migration that is dependent on Ser1718 phosphorylation. [Mol Cancer Res] Abstract

COT Phosphorylates Prolyl-Isomerase Pin1 to Promote Tumorigenesis in Breast Cancer
Scientists identified MAP3K-related serine-threonine kinase as a kinase responsible for phosphorylation of Pin1 Ser16. COT interacts with and phosphorylates Pin1 on Ser16. Consequently, Pin1 Ser16 phosphorylation by COT increases cyclin D1 abundance and enhances tumorigenecity of MCF7 cells. [Mol Carcinog] Abstract

Crosstalk between VEGF and MTA1 Signaling Pathways Contribute to Aggressiveness of Breast Carcinoma
The metastasis associated protein (MTA1) was expressed and purified to evaluate its angiogenic potential. In both MCF-7 and MDA-MB-231 cells, endogenous MTA1 protein was localized in the nucleus; while added recombinant MTA1 protein was bound to cell membrane as per immunofluorescence data. [Mol Carcinog] Abstract

RANK Expression on Breast Cancer Cells Promotes Skeletal Metastasis
Researchers demonstrated that higher RANK expression in MDA-MB-231 breast cancer cells (MDA-231-RANK cells) is sufficient to confer a significantly greater metastatic growth rate in the bone compared with MDA-MB-231 cells which do not express high levels of RANK. [Clin Exp Metastasis] Abstract

BTG1 Expression Correlates with the Pathogenesis and Progression of Breast Carcinomas
Researchers aimed to analyze the expression and clinical significance of B cell translocation gene 1 (BTG1) in breast carcinoma, and its biological effect in a breast cancer cell line by BTG1 overexpression. [Tumor Biol] Abstract

Combined Wnt/β-Catenin, Met, and CXCL12/CXCR4 Signals Characterize Basal Breast Cancer and Predict Disease Outcome
Researchers identified the chemokine system CXCL12/CXCR4 as a crucial driver of Wnt-Met tumors, given that compound-mutant mice also deficient in the CXCR4 gene were tumor resistant. Wnt-Met activation rapidly expanded a population of cancer-propagating cells, in which the two signaling systems control different functions, self-renewal and differentiation. [Cell Rep] Full Article | Graphical Abstract

CLINICAL RESEARCH

CD44 Is Prognostic for Overall Survival in the NCI Randomized Trial on Breast Conservation with 25 Year Follow-Up
Scientists evaluated CD44 as a potential marker of long-term breast cancer outcomes. Tissue specimens from patients treated on the National Cancer Institute (NCI) 79-C-0111 randomized trial of breast conservation versus mastectomy between 1979 and 1987 were collected, and immunohistochemistry was performed using the standard isoform of CD44. [Breast Cancer Res Treat] Abstract

The Relationship between Lymphovascular Invasion and Angiogenesis, Hormone Receptors, Cell Proliferation and Survival in Patients with Primary Operable Invasive Ductal Breast Cancer
Investigators examined the prognostic value of tumor lymphovascular invasion and microvessel density compared with that of established prognostic factors in invasive ductal breast cancer. [BMC Clin Pathol] Abstract | Full Article

Read White Paper:  Increase Success Rate Of Compounds In Toxicity Testing
 
REVIEWS
MicroRNAs Delivered by Extracellular Vesicles: An Emerging Resistance Mechanism for Breast Cancer
Resistance to chemotherapy and endocrine therapy as well as targeted drugs is a major problem in treatment of breast cancer. In this review, the authors highlight recent studies regarding extracellular vesicle-mediated microRNA delivery in formatting drug resistance. [Tumor Biol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
 
SCIENCE NEWS
Merrimack Pharmaceuticals’ MM-121 Demonstrates Positive Signal in Two Phase II ER/PR+ Breast Cancer Studies
Merrimack Pharmaceuticals, Inc. announced the results of two Phase II studies evaluating MM-121 in the treatment of women with ER/PR+, HER2 negative breast cancer. [Merrimack Pharmaceuticals, Inc.]
Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.
 
INDUSTRY NEWS
Genomic Health and Almac Group Enter Exclusive In-Licensing Agreement to Develop and Commercialize Anthracycline Chemotherapy Benefit Test for High Risk Breast Cancer
Genomic Health, Inc. and ALMAC GROUP Ltd jointly announced that Genomic Health will exclusively license Almac Group’s technology and intellectual property to further develop, validate and subsequently commercialize a multi-gene test to predict benefit from DNA damage-based chemotherapy drugs, such as the commonly used anthracycline-based regimens, in breast cancer. [Genomic Health, Inc.] Press Release

BioZorb Surgical Marker Provides New Tool for Breast Cancer Patients
Focal Therapeutics announced that its BioZorbâ„¢ three-dimensional tissue marker has now been successfully used in over 100 patients – marking a significant milestone for the company and the field of post-surgical radiation treatment for breast cancer. [BusinessWire] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW European Network of Breast Development and Cancer Labs 2014
May 8-10, 2014
Weggis, Switzerland

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW PhD Position – Integrated Classification of Breast Cancers to Optimize Treatment Protocols (Radboud University Nijmegen Medical Centre)

Postdoctoral Researcher – National Breast Cancer Research Institute (NUI Galway)

PhD Candidate – Wnt-Signaling and Stem Cell Biology in the Mammary Gland (University of Amsterdam)

Assistant, Associate, or Research Professor – Breast Cancer (Indiana University School of Medicine)

Postdoctoral Fellow – Breast Cancer Stem Cell Biology (UC – College of Medicine)

Postdoctoral Position – Computational Biology and Cancer Genomics (Albert Einstein College of Medicine)

Postdoctoral Position – Computational Biology of Cancer (Gustave Roussy Cancer Institute)

PhD Position – Breast Cancer Bone Metastasis Formation (Claude Bernard University Lyon 1)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Learn more about Mammary Cell News: Archives | Events | Contact Us